SGLT2i DI Flashcards Preview

PHM 602- Diabetes > SGLT2i DI > Flashcards

Flashcards in SGLT2i DI Deck (25)
Loading flashcards...
1
Q

SGLT2i MoA

A

Increases urinary glucose excretion

2
Q

SGLT2i drugs

A

Canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), ertugliflozin (Steglatro)

3
Q

Canagliflozin brand name

A

Invokana

4
Q

Dapagliflozin brand name

A

Farxiga

5
Q

Empagliflozin brand name

A

Jardiance

6
Q

Ertugliflozin brand name

A

Steglatro

7
Q

Canagliflozin dosing

A

100-200mg PO QD

8
Q

Dapagliflozin dosing

A

5-10mg PO QD

9
Q

Empagliflozin dosing

A

10-25mg PO QD

10
Q

Ertugliflozin dosing

A

5-15mg PO QD

11
Q

SGLT2i side effects

A

Genital mycotic infections, UTI, ketoacidosis, weight loss, increased urination

12
Q

Side effects specific to canagliflozin

A

lower limb amputation, fractures, hyperkalemia

13
Q

Side effects specific to dapagliflozin

A

bladder cancer

14
Q

SGLT2i drug interactions

A

hypotension if the patient is on an ACEi/ARB, diuretics, digoxin

15
Q

SGLT2i CI

A

eGFR <30 mL/min

16
Q

SGLT2i counseling

A

Take once a day at the same time (preferably in the morning), discuss yeast infections/UTIs in women, circumcision status, UTIs, and penile discharge in men

17
Q

SGLT2i clinical pearls

A

High A1C lowering, no hypoglycemia, weight loss

18
Q

SGLT2is with CKD benefit

A

Canagliflozin and dapagliflozin

19
Q

SGLT2is with HF benefit

A

Empagliflozin and dapagliflozin

20
Q

SGLT2is with ASCVD benefit

A

Canagliflozin, empagliflozin, dapagliflozin

21
Q

SGLT2i considerations

A

Gangrene, DKA, amputations, increased LDL

22
Q

SGLT2i monitoring

A

FBG/PPG, UTI, yeast infection, BP

23
Q

SGLT2i peak effect

A

4-6 weeks

24
Q

ADA guidelines on SGLT2is

A

Use if ASCVD risk is high, CKD, HF, to minimize hypoglycemia, weight loss

25
Q

AACE guidelines on SGLT2is

A

Third-line option after metformin and GLP-1 RA